. The treatment details of the patients with AE-AML. 63 patients received the '3+7' regimens consisting of daunorubicin (DNR) (n=23) and idarubicin (IDA) (n=36) and other anthracyclines (n=4) for 3 days and cytarabine (Ara-C) at 100-150 mg/m 2 per day for 7 days as induction chemotherapy for 1-2 cycles. A total of 59 cases achieved complete remission (CR) after induction therapy, and 3 without attaining CR received salvage chemotherapy. After CR (n=62), 31 patients were mainly treated with standard-dose Ara-C-based (SDAC-based) regimen; the other 31 cases were mainly treated with intermedium-dose Ara-C-based (IDAC-based) regimen. Allogeneic-hematopoietic stem cell transplantation (Allo-HSCT) was performed in 13 patients. AE-AML, AML1-ETO-positive acute myeloid leukemia.
. The consistency of gene sequencing with next generation sequencing (NGS) and Sanger sequencing. The positive and negative detection of , NPM1, JAK2 (V617F) and DNMT3A (R882) mutations showed 100% consistency between the NGS and Sanger sequencing. FLT3, Fms related tyrosine kinase 3; c-KIT, KIT proto-oncogene, receptor tyrosine kinase; NPM1, nucleophosmin 1; JAK2, Janus kinase 2; DNMT3A, DNA methyltransferase 3α. Figure S3 . c- KIT (exon 8, 17) and ASXL1 mutations were poor prognostic factors in the patients receiving either SDAC-or IDAC-based consolidation. Among the patients with SDAC-based consolidation: (A) c- KIT (exon 8, 17) vs. others: DFS: 22.4±5.6 vs. 33.1±5.1%, P=0.218; OS: 24.4±5.9 vs. 33.2±4.8%, P=0.204. (C) ASXL1 mutation vs. ASXL1-WT: DFS: 13.3±2.5 vs. 34.0±4.8%, P=0.005; OS: 13.3±2.5 vs. 36.5±5.1%, P=0.003. (B) Among the patients with IDAC-based regimens as consolidation: c- KIT (exon 8, 17) vs. others: DFS: 41.5±9.8 vs. 73.8±6.7%, P=0.026; OS: 49.0±10.8 vs. 78.7±4.2%, P=0.052. There were only two patients with ASXL1 mutation in the sub-group with IDAC-based regimens as consolidation; no further sub-group analysis of survival was considered. c-KIT, KIT proto-oncogene, receptor tyrosine kinase; ASXL1, ASXL transcriptional regulator 1; SDAC-based, standard-dose Ara-C-based regimen; IDAC-based, intermediate-dose cytarabine. 
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The 50 genes (upper region of table) listed in the white cells come from the Ion AmpliSeq Cancer Hotspot Panel V2 kit (Thermo Fisher Scientific). The 17 genes listed in the gray cells (bottom region of table) are the common mutant genes being reported to occur in AML and newly added to our new panel. MAO, median age of onset; EML, extramedullary leukemia; BMB, bone marrow blast; ACA, additional chromosome abnormality; CR, complete remission; MMR, major molecular remission; CIR, cumulative incidence of relapse; CID, cumulative incidence of death. a Cumulative CR rate after two course of induction therapy. b MMR was defined as a >3-log reduction in AML1-ETO mRNA transcript levels compared with those during pre-treatment and the checking time point was after two cycles of consolidation.
